LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)

Ch Barrios ,Tao Xu ,Roberto Hegg ,E Shearer-Kang ,Ml Telli ,M Dieterich ,Kevin Punie ,Ki‐Hong Jung ,Nadia Harbeck ,Zoe June Assaf ,Luciana Molinero ,Shigehira Saji ,Jean François Boileau ,H.a Zhang ,Joohyuk Sohn ,Andreas Koehler ,M Liste Hermoso ,Hiroji Iwata ,Sy Chui ,Ea Mittendorf

doi:10.1016/j.esmoop.2023.101571

Abstract

LBA1 Final analysis of the placebo-controlled randomised phase III IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)

Full Text